List of Excipients in Branded Drug RUGBY FLUTICASONE PROPIONATE NASAL

« Back to Dashboard

Generic Drugs Containing RUGBY FLUTICASONE PROPIONATE NASAL

Company	Ingredient	NDC	Excipient
Rugby Laboratories	fluticasone propionate	0536-1183	BENZALKONIUM CHLORIDE
Rugby Laboratories	fluticasone propionate	0536-1183	CARBOXYMETHYLCELLULOSE SODIUM
Rugby Laboratories	fluticasone propionate	0536-1183	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in RUGBY FLUTICASONE PROPIONATE NASAL?

# Of NDCs	Excipient
1	AQUA
6	BENZALKONIUM CHLORIDE
5	CARBOXYMETHYLCELLULOSE SODIUM

Rugby Fluticasone Propionate Nasal Spray: Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Rugby Fluticasone Propionate Nasal is a generic intranasal corticosteroid containing fluticasone propionate, generally delivered as 50 mcg per spray. Its commercial position is based on low-cost substitution for Flonase and private-label distribution rather than patent exclusivity. The formulation uses a conventional aqueous suspension excipient system designed to suspend a poorly water-soluble corticosteroid, control microbial growth, support spray performance, and maintain acceptable nasal tolerability.

The strongest opportunities are private-label expansion, preservative-free or low-irritation variants, improved device performance, pediatric usability, e-commerce packaging, and supply-chain differentiation. A new formulation or device would require regulatory and comparative-performance work because changes to excipients, metering pumps, spray pattern, plume geometry, or dose uniformity can affect therapeutic equivalence.

What is Rugby Fluticasone Propionate Nasal Spray?

Rugby Fluticasone Propionate Nasal is an intranasal product containing fluticasone propionate, a synthetic glucocorticoid used for allergic rhinitis. The product is generally marketed as a generic or store-brand alternative to Flonase Allergy Relief.

Attribute	Product profile
Active ingredient	Fluticasone propionate
Dosage form	Metered-dose nasal spray
Typical strength	50 mcg per spray
Therapeutic class	Intranasal corticosteroid
Primary indication	Relief of nasal symptoms associated with seasonal and perennial allergic rhinitis
Regulatory pathway	FDA-approved nasal spray product; generic products generally rely on an ANDA or approved labeling pathway
Reference product	Flonase, formerly prescription and later approved for OTC use
Biosimilar exposure	None; fluticasone propionate is a chemically synthesized small molecule
Primary commercial model	Generic, private-label, retail, pharmacy, and e-commerce distribution

The active drug is present as a suspension rather than a simple aqueous solution because fluticasone propionate has very low water solubility. The excipient system must keep drug particles uniformly dispersed during storage and use.

What excipients are used in Rugby fluticasone propionate nasal spray?

Public labeling for fluticasone propionate nasal spray products identifies a conventional excipient platform comprising suspending agents, tonicity and bulking components, surfactants, preservatives, alcohols, and purified water. Product-specific labeling should control any final commercial or regulatory assessment.

Excipient category	Common ingredient in the product class	Commercial and technical function
Suspending agent	Microcrystalline cellulose and carboxymethylcellulose sodium	Maintains suspension stability and controls rheology
Bulking or tonicity agent	Dextrose	Supports formulation tonicity and contributes to product feel
Surfactant	Polysorbate 80	Improves wetting and dispersion of fluticasone propionate particles
Preservative	Benzalkonium chloride	Controls microbial growth in a multidose aqueous container
Antimicrobial or solvent component	Phenethyl alcohol	Supports preservation and formulation robustness
Vehicle	Purified water	Continuous phase for the nasal suspension

Comparable fluticasone propionate nasal spray labels list microcrystalline cellulose and carboxymethylcellulose sodium, dextrose, polysorbate 80, benzalkonium chloride, phenethyl alcohol, and purified water as inactive ingredients.[1] The exact concentrations, particle-size specifications, manufacturing order, and device settings are proprietary or product-specific.

Why the formulation is a suspension

Fluticasone propionate is lipophilic and practically insoluble in water. A suspension allows the drug to be delivered in an aqueous nasal spray while maintaining a commercially practical dose. The critical formulation attributes are:

• Particle-size distribution of the active ingredient
• Sedimentation rate
• Redispersibility after storage
• Viscosity and yield behavior
• Spray-content uniformity
• Droplet-size distribution
• Plume geometry
• Pump priming and re-priming performance
• Microbial quality
• Nasal tolerability

A formulation that appears chemically equivalent can still fail performance testing if the drug settles rapidly, agglomerates, clogs the pump, or produces inconsistent dose delivery.

How does the excipient system create commercial value?

The core excipient platform is mature and inexpensive. Its value is operational rather than patent-driven. Proper excipient selection can reduce batch failures, improve fill-finish throughput, minimize pump clogging, and support consistent dose delivery across the product shelf life.

Suspension stability

Microcrystalline cellulose and carboxymethylcellulose sodium provide a structured vehicle that slows sedimentation. The formulation must remain sufficiently fluid for actuation while retaining enough structure to prevent rapid settling.

The principal manufacturing risks are incomplete hydration, uncontrolled viscosity, air entrapment, and nonuniform active distribution. These risks can increase content-uniformity failures and create variable spray performance.

Wetting and dispersion

Polysorbate 80 reduces interfacial tension and helps wet fluticasone propionate particles. Excess surfactant can create foaming, affect sensory properties, or interact with packaging components. Insufficient surfactant can cause poor dispersion and particle agglomeration.

Preservation

Benzalkonium chloride and phenethyl alcohol provide antimicrobial protection in a multidose package. The preservative system must be evaluated against the final formulation, container closure, and microbial challenge profile. Preservative concentration cannot be optimized independently of nasal tolerability.

Benzalkonium chloride has been associated with irritation concerns in some intranasal products, particularly with chronic exposure. That concern creates a commercial opening for preservative-free or alternative-preservative products, but any change requires robust microbial-control and device-validation data.

Sensory performance

Patients judge nasal sprays by immediate attributes such as odor, taste, throat drip, nasal burning, wetness, and post-dose irritation. These attributes are influenced by excipients, viscosity, droplet size, spray force, and plume geometry. A technically stable formulation can lose market share if the device produces excessive runoff or unpleasant taste.

What patents protect Rugby fluticasone propionate nasal spray?

The commercial product is unlikely to depend on enforceable composition-of-matter exclusivity. Fluticasone propionate and the principal fluticasone nasal-spray technology have been available for generic development for many years.

IP category	Current commercial relevance
Fluticasone propionate molecule	No meaningful new-molecule exclusivity for a generic nasal product
Original Flonase formulation patents	Historical relevance; primary blocking periods have expired
Basic nasal-spray suspension technology	Generally mature and difficult to protect broadly
Device patents	Potentially relevant if a specific pump, actuator, or dose counter is proprietary
Preservative-free formulation	Potential source of narrower formulation claims
Spray-pattern or plume-control technology	Potential source of device or combination claims
Manufacturing process	May support trade secrets or narrow process claims
Method-of-use claims	Usually limited commercial value for established allergic-rhinitis indications

A competitive diligence review should distinguish between patents listed for an innovator product and patents that can actually block a Rugby-branded generic. Patent listing in the FDA Orange Book does not automatically establish infringement risk for every generic product, and OTC branding arrangements may involve different approval and distribution structures.[2]

When does Rugby fluticasone propionate nasal lose exclusivity?

Rugby Fluticasone Propionate Nasal does not have a separate, publicly established exclusivity period comparable to a new chemical entity. The product competes in a mature generic market.

Flonase was converted from prescription to OTC status in the United States after FDA approval of the supplemental application for Flonase Allergy Relief in 2014.[3] That switch created a large OTC market but did not provide a durable barrier to generic competition. FDA-approved generic and store-brand fluticasone propionate nasal sprays can compete on price, distribution, packaging, and retail placement.

The practical exclusivity timeline is therefore:

Event	Timing or status
Fluticasone propionate introduced as a prescription product	Historical
Flonase prescription product established	Historical
Flonase OTC switch approved	2014
Broad generic and store-brand competition	Established
Rugby product protection	Primarily commercial and contractual, not patent-based
Current market barrier	Regulatory equivalence, supply reliability, retail access, and brand position

What is the Orange Book status of fluticasone propionate nasal spray?

Fluticasone propionate nasal spray is associated with FDA-approved prescription and generic drug applications. Orange Book analysis should be conducted at the application and dosage-form level because the listed patents, therapeutic equivalence codes, and application status can differ among products.[2]

For a mature generic product, the principal Orange Book questions are:

1. Whether the relevant reference listed drug remains active.
2. Whether the Rugby product has an FDA therapeutic-equivalence code.
3. Whether any listed patents remain unexpired.
4. Whether the product was approved through an ANDA or another application route.
5. Whether the marketed presentation matches the approved dosage form and strength.

The regulatory barrier is usually demonstration of pharmaceutical equivalence and bioequivalence or comparable in vitro performance, not reliance on new clinical efficacy data.

Which companies are challenging Rugby fluticasone propionate nasal?

Rugby operates in a crowded field that includes national generic suppliers, pharmacy chains, mass retailers, online retailers, and contract manufacturers. Competitive products include store brands and generic versions associated with companies such as Perrigo, Apotex, Hikma, and other FDA-approved suppliers, depending on the specific package and current market availability.

The principal competitive pressure comes from:

• Retail private-label products
• Amazon and online pharmacy listings
• National generic distributors
• OTC allergy brands
• Seasonal promotional pricing
• Retailer-exclusive packaging
• Contract manufacturing bids

Publicly available information does not establish a major, product-specific Paragraph IV litigation campaign against Rugby Fluticasone Propionate Nasal. The relevant litigation risk is more likely to arise from supplier disputes, device patents, manufacturing contracts, or private-label commercial arrangements than from a new composition-of-matter challenge.

What formulation patents could protect a next-generation product?

A conventional fluticasone propionate suspension has limited room for broad composition claims because the main excipient architecture is established. More defensible IP could focus on a measurable technical improvement.

Preservative-free nasal spray

A preservative-free multidose product could claim a combination of:

• Low-bioburden manufacturing
• Antimicrobial container or closure technology
• One-way valve architecture
• Improved pump isolation
• Microbial-control process parameters
• Specific suspension rheology
• Stable delivered-dose performance

The commercial rationale is strong because preservative concerns are relevant to chronic allergy treatment. The regulatory burden is also high. A preservative-free multidose system must demonstrate microbial robustness through container-closure and in-use studies.

Improved suspension platform

Potential formulation claims could cover:

• Narrow active-particle size distribution
• Specific cellulose-to-drug ratios
• Defined viscosity ranges
• Improved redispersibility
• Reduced sedimentation
• Lower actuation variability
• Reduced throat deposition

Broad claims are likely to face prior-art challenges. Narrow claims tied to validated performance may have greater defensibility.

Device and spray-pattern claims

The pump and actuator can create differentiation through:

• Lower residual volume
• More consistent metering
• Easier priming
• Reduced clogging
• Dose counters
• One-handed operation
• Child-resistant or travel-protective packaging
• Reduced plume variability

A device-led product may require a 505(b)(2) strategy, a new ANDA evaluation, or another FDA pathway depending on the degree of change and relationship to the reference product.

What generic launch risks exist for Rugby fluticasone propionate nasal?

Generic launch risk is concentrated in formulation-device equivalence and commercial execution.

Risk	Effect on launch
Suspension instability	Dose nonuniformity and product recalls
Pump clogging	Consumer complaints and lost repeat purchases
Inadequate microbial control	Batch rejection or regulatory action
Different spray pattern	Possible therapeutic-equivalence or usability concerns
Nasal irritation	Lower adherence and retailer returns
Supplier concentration	Stockouts during allergy season
Retail price compression	Reduced gross margin
Seasonal demand volatility	Excess inventory or missed sales
Packaging errors	OTC labeling and compliance exposure
Device change	Additional comparative-performance requirements

Allergy products are highly seasonal. A supplier failure during spring demand can erase the advantage of a low-cost formulation. Dual sourcing for the pump, active pharmaceutical ingredient, and critical cellulose excipients can have greater commercial value than a minor reduction in unit formulation cost.

What commercial opportunities exist for Rugby fluticasone propionate nasal?

Private-label and retailer expansion

The most immediate opportunity is additional private-label placement across pharmacies, supermarkets, mass merchants, warehouse clubs, and online platforms. The active ingredient is well recognized, and consumer conversion from Flonase can be driven by price and equivalent labeled use.

Retailer-specific packaging, multipacks, twin packs, and seasonal displays can increase volume without changing the formulation.

Premium generic positioning

A higher-margin product could use:

• Preservative-free packaging
• A lower-irritation excipient profile
• A redesigned actuator
• A dose counter
• Improved child or senior usability
• Reduced packaging weight
• Better travel protection

The product would need a clear consumer benefit because the base drug is heavily commoditized.

Pediatric and caregiver-focused design

Potential opportunities include a gentler actuator force, clearer dose tracking, easier priming, and packaging that reduces handling errors. Pediatric positioning must remain within approved labeling and cannot imply unapproved claims.

Sustainability

Commercial differentiation may come from:

• Lower-plastic packaging
• Recyclable secondary cartons
• Reduced shipping volume
• Lower-residue pumps
• Concentrated packaging formats where technically feasible

Environmental claims must match validated packaging and lifecycle data. The pump system remains a constraint because nasal-spray devices combine plastic components, mechanical parts, and product-contact materials.

Geographic expansion

The formulation platform can support expansion into markets with allergic rhinitis demand, subject to local registration, labeling, preservative requirements, device standards, and import controls. European and other non-U.S. markets may apply different rules to OTC status, excipients, nasal-device qualification, and pharmacopoeial testing.

How strong is the patent estate for Rugby fluticasone propionate nasal?

The patent estate is weak as a blocking platform but potentially useful as a defensive or incremental-development platform.

Patent dimension	Assessment
Active ingredient	Low blocking value for a generic entrant
Conventional excipients	Low-to-moderate value because of extensive prior art
Preservative-free system	Moderate potential if tied to a specific container and performance profile
Device	Moderate potential for differentiated pump and actuator designs
Manufacturing process	Moderate value, often better protected as know-how
Method of use	Low value for established allergic-rhinitis indications
Trade secrets	High practical value for suspension processing and filling controls
Market exclusivity	Primarily based on supply, retail access, and branding

Trade secrets may provide more practical protection than patents for mixing order, hydration conditions, active wetting, bulk-hold time, and filling parameters.

What litigation and settlement issues affect the product?

No major public settlement framework is central to the commercial position of Rugby Fluticasone Propionate Nasal. Mature generic nasal sprays typically face lower litigation intensity than newer specialty medicines.

The relevant legal issues are more likely to involve:

• ANDA certification and patent statements
• Device or actuator patents
• False or misleading OTC advertising
• Labeling compliance
• Product liability for improper use
• Contract manufacturing disputes
• Supply and quality agreements
• Private-label exclusivity clauses
• Antitrust issues involving generic supply

A new formulation strategy should include a freedom-to-operate review covering the formulation, pump, actuator, dose counter, container closure, and claimed spray characteristics.

Key Takeaways

• Rugby Fluticasone Propionate Nasal is a mature generic or private-label intranasal corticosteroid product based on fluticasone propionate.
• The conventional excipient system uses cellulose-based suspension control, dextrose, polysorbate 80, benzalkonium chloride, phenethyl alcohol, and purified water.
• The main technical challenge is maintaining suspension uniformity and consistent metered delivery through the full shelf life.
• Patent-based blocking power is limited because fluticasone propionate nasal spray is a mature generic category.
• The strongest IP opportunities are preservative-free multidose systems, pump and actuator improvements, spray-pattern control, and manufacturing know-how.
• The strongest commercial opportunities are private-label expansion, retailer exclusives, premium generic positioning, pediatric usability, and seasonal supply reliability.
• There is no biosimilar risk because fluticasone propionate is a small-molecule drug.
• Generic launch risk is concentrated in device performance, microbial control, nasal tolerability, supply continuity, and retail price competition.

FAQs

Is Rugby fluticasone propionate nasal spray the same as Flonase?

It contains the same active ingredient, fluticasone propionate, at the standard 50 mcg-per-spray strength used in the Flonase product class. Excipients, device characteristics, labeling, and packaging can differ by manufacturer.

Does benzalkonium chloride make the Rugby nasal spray less attractive?

It can create a commercial disadvantage for consumers seeking preservative-free products, particularly for chronic use. Its presence also supports a product-development opportunity for preservative-free container and pump systems.

Can a company patent a new fluticasone nasal-spray excipient combination?

Yes, but broad claims are difficult because the formulation field has extensive prior art. Patent strength is more likely when the excipient combination is linked to a measurable improvement in stability, spray uniformity, tolerability, microbial control, or device performance.

Is fluticasone propionate nasal spray eligible for an OTC private-label launch?

An OTC private-label launch depends on the applicable FDA approval pathway, labeling, product-specific regulatory status, and manufacturing arrangement. The 2014 Flonase OTC switch established the commercial category, but a private-label product still requires an appropriate FDA-compliant approval basis.[3]

What is the highest-value improvement for a new Rugby-compatible product?

A preservative-free multidose system with reliable microbial control and a low-clogging pump offers the clearest premium opportunity. A lower-cost conventional formulation can generate volume, but it has limited differentiation in a price-driven generic market.

References

1. National Library of Medicine. (n.d.). DailyMed: Fluticasone propionate nasal spray labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2014, October 10). FDA approves Flonase Allergy Relief for over-the-counter use. https://www.fda.gov/

4. U.S. Pharmacopeia. (2023). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (1999). Guidance for industry: Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation. https://www.fda.gov/